https://www.selleckchem.com/products/Axitinib.html
BVS, when compared with DES, resulted in higher rates of target lesion revascularization (TLR) (OR, 2.20; 95% CI, 1.12-3.64; P = .02) and stent/scaffold thrombosis (ST/ScT) (OR = 2.35, 95% CI 1.13-4.89, P = .02). When TLR due to device thrombosis were excluded, the difference in risk estimates between the 2 groups was no longer significant (OR 1.67, 95% CI 0.73-3.82, P = .22). The risk for all-cause death (OR = 1.32 95% CI 0.61-2.88, P = .48), cardiac death (OR = 1.29, 95% CI 0.58-2.86 P = .52), target vessel myocardial infarction (OR
Like
Comment
Share
